Yang IA, Holloway JW, Fong KM.

Genetic susceptibility to lung cancer and co-morbidities

J Thorac Dis. 2013 Oct;5 Suppl 5:S454-62. doi: 10.3978/j.issn.2072-1439.2013.08.06. Review.

Article predisposition génétique 2

Yamamoto H1, Higasa K, Sakaguchi M, Shien K, Soh J, Ichimura K, Furukawa M, Hashida S, Tsukuda K, Takigawa N, Matsuo K, Kiura K, Miyoshi S, Matsuda F,Toyooka S.

Novel germline mutation in the transmembrane domain of HER2 in familial lung adenocarcinomas

J Natl Cancer Inst. 2014 Jan;106(1):djt338. doi: 10.1093/jnci/djt338. Epub 2013 Dec 7.

Article HER2

Solomon B1, Varella-Garcia M, Camidge DR.

ALK gene rearrangements: a new therapeutic target in a molecularly defined subset of non-small cell lung cancer

J Thorac Oncol. 2009 Dec;4(12):1450-4. doi: 10.1097/JTO.0b013e3181c4dedb.

Article ALK

Kaiser J.

Cancer research. Looking for a target on every tumor.

Science. 2009 Oct 9;326(5950):218-20. doi: 10.1126/science.326_218.

Article Thérapies ciblées

Roswit B, Patno ME, Rapp R, Veinbergs A, Feder B, Stuhlbarg J, Reid CB.

The survival of patients with inoperable lung cancer: a large-scale randomized study of radiation therapy versus placebo

Radiology. 1968 Apr;90(4):688-97.

Article princeps : Radiothérapie vs placebo dans le cancer bronchique inopérable

Temel JS, Greer JA, Muzikansky A, Gallagher ER, Admane S, Jackson VA, Dahlin CM, Blinderman CD, Jacobsen J, Pirl WF, Billings JA, Lynch TJ.

Early palliative care for patients with metastatic non-small-cell lung cancer

N Engl J Med. 2010 Aug 19;363(8):733-42. doi: 10.1056/NEJMoa1000678.

Article princeps : amélioration de la survie avec des soins de support actifs

Baumann P1, Nyman J, Hoyer M, Wennberg B, Gagliardi G, Lax I, Drugge N, Ekberg L, Friesland S, Johansson KA, Lund JA, Morhed E, Nilsson K, Levin N, Paludan M, Sederholm C, Traberg A, Wittgren L, Lewensohn R.

Article Radiothérapie stéréotaxique Baumann JCO 2009

J Clin Oncol. 2009 Jul 10;27(20):3290-6. doi: 10.1200/JCO.2008.21.5681. Epub 2009 May 4.

Outcome in a prospective phase II trial of medically inoperable stage I non-small-cell lung cancer patients treated with stereotactic body radiotherapy.

Pignon JP, Tribodet H, Scagliotti GV, Douillard JY, Shepherd FA, Stephens RJ, Dunant A, Torri V, Rosell R, Seymour L, Spiro SG, Rolland E, Fossati R, Aubert D, Ding K, Waller D, Le Chevalier T; LACE Collaborative Group.

Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group

J Clin Oncol. 2008 Jul 20;26(21):3552-9. doi: 10.1200/JCO.2007.13.9030. Epub 2008 May 27.

Article princeps Chimiothérapie adjuvante des N1

Song WA, Zhou NK, Wang W, Chu XY, Liang CY, Tian XD, Guo JT, Liu X, Liu Y, Dai WM.

Article Métanalyse chimiothérapie néo-adjuvante dans le cancer bronchique NPC

J Thorac Oncol. 2010 Apr;5(4):510-6. doi: 10.1097/JTO.0b013e3181cd3345.

Survival benefit of neoadjuvant chemotherapy in non-small cell lung cancer: an updated meta-analysis of 13 randomized control trials.

Betticher DC, Hsu Schmitz SF, Tötsch M, Hansen E, Joss C, von Briel C, Schmid RA, Pless M, Habicht J, Roth AD, Spiliopoulos A, Stahel R, Weder W, Stupp R, Egli F, Furrer M, Honegger H, Wernli M, Cerny T, Ris HB.

Article phase II impact pronostique du downstaging médiastinal après chimiothérapie néo-adjuvante (Betticher 2003)

J Clin Oncol. 2003 May 1;21(9):1752-9.

Mediastinal lymph node clearance after docetaxel-cisplatin neoadjuvant chemotherapy is prognostic of survival in patients with stage IIIA pN2 non-small-cell lung cancer: a multicenter phase II trial.

11 -  20  / 22